匹罗卡品致痫大鼠海马神经肽Y中间神经元数目变化及其轴突出芽.pdf
王瑞芳 薛国芳 连霞 高慧中 曹丽君 郑辑英
[摘要] 目的 探討利拉鲁肽对大鼠癫痫持续状态后海马各区神经元凋亡的影响。 方法 将雄性SD大鼠(n=54)随机分为空白对照组(n=6)、匹罗卡品模型组(SE组,n=24)、利拉鲁肽干预组(Liraglutide组,n=24);并根据发作终止后的时间点(12 h,1 d,3 d,7 d)将SE组和Liraglutide组各分为4个亚组(n=6)。采用免疫组化技术检测海马CA3和DG区BCL2和BAX蛋白的表达。 结果 与SE组相比,Liraglutide组在SE后12 h、1 d、3 d时CA3区BCL2表达水平升高(P<0.05),而在SE后7 d时BCL2水平与SE组无差异(P>0.05);在DG区,Liraglutide组在SE后1 d BCL2表达升高(P<0.05),在SE后3 d时表达无差异(P>0.05)。Liraglutide组相较SE组,在SE后12 h,DG区BAX表达开始明显降低(P<0.01);在SE后1 d,CA3区BAX表达降低(P<0.01);且在SE后3 d,Liraglutide组DG区和CA3区BAX表达都高于空白对照组(P<0.05)。 结论 利拉鲁肽通过抑制癫痫持续状态后海马CA3区和DG区神经元凋亡发挥神经保护作用。
[关键词] GLP-1;癫痫;海马;凋亡
[中图分类号] R742.1 [文献标识码] A [文章编号] 1673-9701(2018)10-0032-05
Effects of liraglutide on neuronal apoptosis in each zone of hippocampus in rats with epilepsy induced by pilocarpine
WANG Ruifang1 XUE Guofang2 LIAN Xia2 GAO Huizhong2 CAO Lijun2 ZHENG Jiying2
1.Shanxi Medical University,Taiyuan 030000,China;2.Department of Neurology,Shanxi Medical University Second Hospital,Taiyuan 030000,China
[Abstract] Objective To investigate the effect of liraglutide on neuronal apoptosis in each zone of hippocampus after persistent state of epilepsy in rats. Methods Male SD rats(n=54) were randomly divided into blank control group(n=6), pilocarpine model group (SE group, n=24), and liraglutide intervention group(Liraglutide group, n=24); the SE group and liraglutide group were divided into 4 subgroups(n=6) according to the time point after the termination of attack(12 h, 1 d, 3 d, 7 d). Immunohistochemistry was used to detect the expression of BCL2 and BAX proteins in CA3 and DG zones of hippocampus. Results In the liraglutide group, compared with the SE group, the expression of BCL2 in CA3 zone was increased at 12 hours, 1 day and 3 days after SE(P<0.05). However, there was no difference in BCL2 level compared with SE group at 7 days after SE(P>0.05);in the DG zone, BCL2 expression was increased in liraglutide group one day after SE(P<0.05);there was no difference in expression at 3 days after SE(P>0.05). In the liraglutide group, the expression of BAX was significantly decreased in DG zone at 12 hours after SE compared with SE group(P<0.01);one day after SE, the expression of BAX was decreased in CA3 zone(P<0.01);and 3 days after SE, BAX expression in DG zone and CA3 zone in liraglutide group was higher than that in the blank control group(P<0.05). Conclusion Liraglutide exerts neuroprotective effect by inhibiting apoptosis of neurons in CA3 and DG zones of hippocampus after persistent states of epilepsy.
[Key words] GLP-1;Epilepsy;Hippocampus;Apoptosis
癫痫持续状态(status epilepticus,SE)是神经内科急症,具有较高的致残率和致死率[1,2]。但目前现有的抗癫痫药,如苯二氮类药物地西泮等仅可缓解痫性发作症状,并不能针对SE后癫痫发生发挥作用[3-5]。且SE可能发展为慢性癫痫,甚至难治性癫痫,预后较差[5]。因此,探讨癫痫发生(Epileptogenesis)的机制并寻找能针对癫痫发生的用药成为研究热点。利拉鲁肽是一种胰高血糖素样肽-1(Glucagon-like petide 1,GLP-1)类似物,目前被用于临床2型糖尿病的治疗[6]。近来研究表明,GLP-1类似物能够穿过血脑屏障与脑内GLP-1受体结合,抑制脑内炎性反应、氧化应激、细胞凋亡等病理过程并增强突触可塑性和海马神经元再生,延缓神经系统疾病的发生发展[7,8]。其神经保护作用已在帕金森病(Parkinson's disease,PD)、阿尔茨海默病(Alzheimers disease,PD)、创伤性脑损伤、卒中的动物模型中得到证实;而且GLP-1类似物艾塞那肽对PD的研究已经在临床上得到初步认证[9-12]。因此,本文采用氯化锂-匹罗卡品模型模拟人类颞叶癫痫,观察利拉鲁肽是否能通过抑制SE后海马各区神经元凋亡,发挥神经保护作用。
1 材料与方法
1.1实验动物与实验分组设计
健康雄性Sprague-Dawley(SD)大鼠,重200~250 g,购于北京维通利华实验动物技术有限公司。将54只SD大鼠随机分为三组:空白对照组(n=6)、匹罗卡品模型组(SE组,n=24)和利拉鲁肽干预组(Liraglutide组,n=24);并根据痫性发作终止后的时间点(12 h,1 d,3 d,7 d)将SE组和Liraglutide组各分为4个亚组(n=6)。Liraglutide组在痫性发作终止后腹腔注射利拉鲁肽25 nmol/(kg·d);SE组同时注射等体积生理盐水。基于模型的成功率和死亡率,补充实验大鼠,保证每组动物数量。
1.2 匹罗卡品诱导SE模型
SD大鼠首先按127 mg/kg腹腔注射氯化锂(Sigma-Aldrich),20 h后腹腔给予1 mg/kg硫酸阿托品(天津金耀)来降低外周胆碱能反应,30 min后再给予30 mg/kg盐酸匹罗卡品(MedChem Express)诱导痫性发作。观察大鼠行为学变化,一般在盐酸匹罗卡品注射后30 min内出现痫性发作。Racine分级标准(Racine分级:Ⅳ级:后肢站立伴全身强直性阵挛;Ⅴ级:站立伴摔倒的全身强直性阵挛发作),Ⅳ级及以上持续发作超过30 min认定为SE造模成功。SE后1 h,10 mg/kg地西泮(天津金耀)腹腔注射终止痫性发作。
1.3 免疫组织化学检测海马区BCL2和BAX蛋白表达
腹腔注射5%的水合氯醛(5 mL/kg)麻醉大鼠后,进行心脏灌注。打开胸腔,暴露心脏,将7#输液器针头从心尖部插入,同时剪开右心耳,快速灌入预冷生理盐水约150 mL,待观察到流出液变清亮时,停止灌注;随后,用4%的多聚甲醛(PFA)先快后慢灌注约150 mL。待大鼠四肢、尾巴僵硬后断头取脑,并浸泡于4%PFA中固定。24 h后脑组织脱水、包埋、制作5 μm厚石蜡切片。切片经二甲苯、酒精脱蜡水化后,用3%的过氧化氢溶液室温孵育10 min以灭活内源性的过氧化物酶。随后,以柠檬酸盐缓冲液(pH=6.0)进行抗原修复。一抗包括兔抗鼠anti-BCL2(1∶50,Bioworld technology),兔抗鼠anti-BAX(1∶50,Bioworld technology)分别4℃孵育过夜后,二抗-山羊抗兔IgG(1∶500,博士德)37℃孵育1 h。切片每次孵育后需用0.01 M的磷酸盐缓冲液(PBS,博士德)洗涤3次,每次5 min。滴加辣根过氧化物酶标记的ABC复合物(中山金桥),37℃反应20 min。DAB室温显色约3 min后,自来水终止显色。最后苏木素浸染约1 min,盐酸酒精分化1 s,流水冲洗返蓝后脱水、封片。进行图像分析,用Image pro plus 6.0分别进行海马CA3、DG区阳性细胞计数。
1.4 统计学方法
采用SPSS20.0统计学软件进行分析,计量资料经正态性检验,均符合正态分布,采用均数±标准差(x±s)描述。依据资料性质,多组均数比较采用单因素方差分析(One-way ANOVA),组间两两比较采用Tukey检验。P<0.05为差异有统计学意义。
2 结果
2.1利拉鲁肽增强海马CA3和DG区BCL2表达水平
与空白对照组相比,SE组在SE后12 h海马CA3区BCL2表达明显升高(P<0.05),且在SE后1 d达到峰值(P<0.01);DG区BCL2表达在SE后1 d开始升高(P<0.01),3 d后维持较高水平(P<0.01),7 d后BCL2表达仍高于空白对照组(P<0.05),但低于SE后3 d时的水平。与SE组相比,Liraglutide组在SE后12 h、1 d、3 d时海马CA3区BCL2表达水平升高(P<0.05),而在SE后7 d时BCL2水平与SE组无明显差异(P>0.05);相较SE组,Liraglutide组在海马DG区,SE后1 d BCL2表达升高(P<0.05),在SE后3 d时表达无明显差异(P>0.05)。见图1a(封三)、图1b、圖2a(封三)、图2b。
2.2利拉鲁肽减低海马CA3和DG区BAX表达水平
在SE后12 h,SE组海马DG区BAX表达明显高于空白对照组(P<0.01),且随时间推移而逐渐增加(P<0.01);海马CA3区BAX表达在SE后1 d开始增加(P<0.01),且在3 d后达到峰值,7 d时仍维持较高水平。与SE组相比,Liraglutide组海马DG区BAX水平在SE后12 h开始明显降低(P<0.01),且与空白对照组无明显差异(P>0.05);在SE后3 d BAX表达仍低于SE组(P<0.01),且高于空白对照组(P<0.01)。相较SE组,Liraglutide组在SE后1 d海马CA3区,BAX表达明显降低(P<0.01),但与空白对照组无明显差异(P>0.05);在SE后3 d Liraglutide组BAX较SE组低但高于空白对照组(P<0.05)。见图3a(封三)、图3b、图4a(封三)、图4b。
3 討论
氯化锂-匹罗卡品诱导的SE模型模拟人类颞叶癫痫,在SE后,进入1~2周的潜伏期(此时,SE诱导的脑损伤持续进展),最后可能发展为慢性癫痫[13,14]。研究表明,神经元凋亡在潜伏期癫痫发生过程中发挥重要作用,而氧化应激又是诱导凋亡最主要的原因[15,16]。SE诱导氧化应激,即ROS/RNS上调,其损害细胞膜蛋白、酶和线粒体;ROS/RNS触发的线粒体DNA损伤及电子链功能失用被认为是神经元凋亡的主要因素;线粒体对于ROS/RNS的变化极为敏感,线粒体应激、功能障碍时,细胞内钙离子增加,抗氧化物尤其是谷胱甘肽合成障碍、钙离子依赖的线粒体渗透性转换孔(mitochondrial permeability transition pore,MPTP)开启引起细胞凋亡[15,17,18]。既往研究显示,这些应激反应均可增强突触传导、提高神经元兴奋性,进一步促进癫痫发生[19]。因此,抑制神经元凋亡有可能抑制癫痫发生,延缓疾病进展。ROS产物与线粒体Ca2+共同作用开启MPTP,导致促凋亡分子从线粒体释放到胞浆,通过Caspase途径、线粒体相关蛋白BCL2家族以及凋亡诱导因子(apoptosis-inducing factor,AIF)触发细胞凋亡[20-23]。BCL2家族包括抗凋亡蛋白BCL2、BCL-XL和促凋亡蛋白BAX、BAD等,其主要通过调控BCL2/BAX含量比值发挥作用;当促凋亡蛋白BAX含量远高于抗凋亡蛋白BCL2水平时,促进细胞色素C(Cytc)释放,启动线粒体凋亡[24]。所以,本实验通过检测SE后大鼠海马各区BCL2和BAX蛋白的表达情况来探讨利拉鲁肽能否通过抑制神经元凋亡来发挥神经保护作用。
本实验采用匹罗卡品模型,观察SE后12 h、1 d、3 d、7 d这4个时间点海马CA3区和DG区BCL2/BAX表达情况。结果显示,BCL2表达在SE后12 h就开始明显升高,但在CA3区其表达在1 d后又开始下降,在DG区BCL2表达在7 d后开始下降;海马DG和CA3区BAX表达分别在SE后12 h和1 d开始升高,且持续维持较高水平。SE诱导促凋亡蛋白BAX在SE后12 h开始升高,使得MPTP开启且线粒体外膜通透性增加、促凋亡分子释放到胞浆,激活下游caspase依赖和非依赖性的凋亡通路,促进癫痫发生[25]。而抗凋亡蛋白BCL2在SE后也升高,可能是机体应激状态的自我保护,但在SE后1 d就开始下降,使得BCL2/BAX含量比值下降,协同BAX促进癫痫发生。结果表明,在SE后癫痫发生过程中细胞凋亡持续存在,且继续进展,这与之前的研究结果相一致,SE后BCL2家族迅速被激活,诱导线粒体途径凋亡,并进一步讨论了DG区凋亡情况的变化[16,26]。
有研究[27-29]认为,SE后潜伏期可能成为癫痫治疗的重要时间窗,但现有抗癫痫药并不能针对潜伏期间癫痫发生的病理过程发挥作用。因此,致力于癫痫发生的用药研究成为热点。研究表明,左乙拉西坦、α-细辛醚、西格列汀等可以通过抑制SE后神经炎性反应、细胞凋亡来作用于癫痫发生,从而发挥一定的神经保护作用[20,30,31]。神经元凋亡被认为是SE后促进癫痫发生的重要病理机制,而GLP-1受体激动剂在PD、AD模型中能有效抑制线粒体应激,抑制凋亡[32]。因此,本研究通过检测利拉鲁肽对SE后海马CA3和DG区促凋亡蛋白BAX和抗凋亡蛋白BCL2的表达情况,表明利拉鲁肽在SE后12 h开始发挥作用,但在SE后3 d时,Liraglutide组海马DG区BCL2表达与SE组无统计学差异,BAX表达虽低于SE组却高于空白对照组,表明利拉鲁肽可能通过部分调整BCL2和BAX蛋白表达水平来缓解线粒体应激引起的细胞凋亡,但其对SE后细胞凋亡的抑制具有一定的局限,可能是由于癫痫发生过程的错综复杂性或者利拉鲁肽药物浓度降低所造成的,其机制尚不清楚,有待进一步的研究。
[参考文献]
[1] Brigo F,Bragazzi NL,Lattanzi S,et al.A critical appraisal of randomized controlled trials on intravenous phenytoin in convulsive status epilepticus[J]. European Journal of Neurology,2017,25(3):451-463.
[2] Zeng X,Chen S,Gao Q et al. Corrigendum to "The expression of G protein-coupled receptor kinase 5 and its interaction with dendritic marker microtubule-associated protein-2 after status epilepticus"[J].Epilepsy Res,2017, 138(2017):62-70.
[3] Trandafir CC,Pouliot WA,Dudek FE,et al. Co-administration of subtherapeutic diazepam enhances neuroprotective effect of COX-2 inhibitor,NS-398,after lithium pilocarpine-induced status epilepticus[J]. Neuroscience,2015,284:601-610.
[4] Pitkanen A,Kharatishvili I,Narkilahti S,et al. Administration of diazepam during status epilepticus reduces development and severity of epilepsy in rat[J]. Epilepsy Research,2005,63(1):27-42.
[5] Kantanen AM,Reinikainen M,Parviainen I,et al. Long-term outcome of refractory status epilepticus in adults:A retrospective population-based study[J]. Epilepsy research, 2017,133:13-21.
[6] Iepsen EW,Torekov SS,Holst JJ. Liraglutide for Type 2 diabetes and obesity:A 2015 update[J]. Expert Review of Cardiovascular Therapy,2015,13(7):753-767.
[7] Hamilton A,Holscher C. Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system[J]. Neuroreport,2009,20(13):1161-1166.
[8] Hunter K,Holscher C.Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis[J].BMC neuroscience,2012,13(1):33.
[9] McClean PL,Holscher C. Liraglutide can reverse memory impairment,synaptic loss and reduce plaque load in aged APP/PS1 mice,a model of Alzheimer's disease[J]. Neuropharmacology,2014,76:57-67.
[10] Gejl M,Brock B,Egefjord L,et al. Blood-brain glucose transfer in Alzheimer's disease:Effect of GLP-1 analog treatment[J]. Scientific Reports,2017,7(1):17490.
[11] Kim S,Jeong J,Jung HS, et al. Anti-inflammatory effect of glucagon like peptide-1 receptor agonist, exendin-4, through Modulation of IB1/JIP1 expression and JNK signaling in stroke[J]. Experimental Neurobiology,2017,26(4):227-239.
[12] Li Y,Bader M,Tamargo I,et al. Liraglutide is neurotrophic and neuroprotective in neuronal cultures and mitigates mild traumatic brain injury in mice[J]. Journal of Neurochemistry,2015,135(6):1203-1217.
[13] Biagini G,Rustichelli C,Curia G,et al. Neurosteroids and epileptogenesis[J]. Journal of Neuroendocrinology,2013,25(11):980-990.
[14] 王本國,廖卫平,罗爱华.氯化锂联合匹罗卡品小剂量多次注射诱发癫痫持续状态模型的研究[J].广东医学,2006,27(6):810-812.
[15] Mendez-Armenta M, Nava-Ruiz C, Juarez-Rebollar D, et al. Oxidative stress associated with neuronal apoptosis in experimental models of epilepsy[J]. Oxidative Medicine and Cellular Longevity,2014,2014:293689.
[16] Henshall DC,Engel T. Contribution of apoptosis-associated signaling pathways to epileptogenesis:Lessons from Bcl-2 family knockouts[J]. Frontiers in Cellular Neuroscience,2013,7:110.
[17] Aguiar CCT,Almeida AB,Araujo PVP,et al. Oxidative stress and epilepsy:Literature review[J].Oxidative Medicine and Cellular Longevity,2012,2012:795259.
[18] Rowley S, Patel M. Mitochondrial involvement and oxidative stress in temporal lobe epilepsy[J]. Free Radical Biology & Medicine. 2013,62:121-131.
[19] Cardenas-Rodriguez N,Huerta-Gertrudis B,Rivera-Espinosa L,et al. Role of oxidative stress in refractory epilepsy:Evidence in patients and experimental models[J].International Journal of Molecular Sciences,2013,14(1):1455-1476.
[20] Nader MA,Ateyya H,El-Shafey M,et al. Sitagliptin enhances the neuroprotective effect of pregabalin against pentylenetetrazole-induced acute epileptogenesis in mice:Implication of oxidative,inflammatory,apoptotic and autophagy pathways[J].Neurochemistry International,2017, 115:11-23.
[21] Meng DW,Liu HG,Yang AC,et al. Stimulation of anterior thalamic nuclei protects against seizures and neuronal apoptosis in hippocampal CA3 region of kainic acid-induced epileptic rats[J]. Chinese Medical Journal,2016, 129(8):960.
[22] Emerit J,Edeas M,Bricaire F. Neurodegenerative diseases and oxidative stress[J].Biomedicine & Pharmacotherapy,2004,58(1):39-46.
[23] Kajta M.Apoptosis in the central nervous system:Mechanisms and protective strategies[J].Pharmacological Reports,2004,56(6):689-700.
[24] Annis MG,Soucie EL,Dlugosz PJ,et al.Bax forms multispanning monomers that oligomerize to permeabilize membranes during apoptosis[J].The EMBO Journal,2005, 24(12):2096-2103.
[25] Chipuk JE,Moldoveanu T,Llambi F,et al. The BCL-2 Family Reunion[J]. Molecular Cell. 2010,37(3):299-310.
[26] Akcali KC,Sahiner M,Sahiner T. The role of bcl-2 family of genes during kindling[J]. Epilepsia,2005,46(2):217-223.
[27] Loscher W,Brandt C.Prevention or modification of epileptogenesis after brain insults:experimental approaches and translational research[J].Pharmacological Reviews,2010,62(4):668-700.
[28] Pitkanen A. Therapeutic approaches to epileptogenesis-hope on the horizon[J]. Epilepsia,2010,51(Suppl 3):2-17.
[29] Jensen FE. Introduction Posttraumatic epilepsy:Treatable epileptogenesis[J]. Epilepsia,2009,50(Suppl 2):1-3.
[30] Kikuyama H,Hanaoka T,Kanazawa T,et al. The mechanism of anti-epileptogenesis by levetiracetam treatment is similar to the spontaneous recovery of idiopathic generalized epilepsy during adolescence[J]. Psychiatry Investigation,2017,14(6):844-850.
[31] Liu HJ,Lai X,Xu Y,et al. Alpha-asarone attenuates cognitive deficit in a pilocarpine-induced status epilepticus rat model via a decrease in the nuclear factor-kappaB activation and reduction in microglia neuroinflammation[J]. Frontiers in Neurology,2017,8:661.
[32] Jalewa J,Sharma MK,Gengler S,et al. A novel GLP-1/GIP dual receptor agonist protects from 6-OHDA lesion in a rat model of Parkinson's disease[J]. Neuropharmacology,2017,117:238-248.
(收稿日期:2017-11-25)